Pharmacogenetic and Pharmacokinetic Study of Clopidogrel
NCT ID: NCT01968499
Last Updated: 2017-10-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1805 participants
OBSERVATIONAL
2011-03-31
2017-10-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Published data linking clopidogrel non-responsiveness to adverse ischaemic events lead to the suggestion that the magnitude of platelet inhibition by clopidogrel can be monitored and individually adjusted. This has been tested in randomised clinical trials (ARCTIC, GRAVITAS and TRIGGER-PCI), but despite reducing platelet reactivity, a strategy of therapy adjustment based on platelet function monitoring did not reduce the incidence of cardiac ischaemic events1, which indicates that most pharmacodynamical tests monitored anti-platelet treatment failed so far.
We accordingly performed this registration study to investigate whether the pharmacogenetic and pharmacokinetic factors are associated with clopidogrel low response as well as clinical outcome, and aimed to provide new targets for the individualized anti-platelet treatment.
Inclusion criteria:
1. Successively recruit all patients who receive stent implantation and take aspirin 100 mg and clopidogrel 75 mg once daily (7:00 a.m.) for more than 5 days.
2. Patient aged \>18 years;
3. Signed inform consent.
Exclusion criteria:
1. intolerant with aspirin or clopidogrel treatment (e.g. allergic reactions or gastrointestinal bleeding);
2. taking medication that could interfere with the antiplatelet efficacy of clopidogrel (e.g. vitamin K antagonists, direct oral anticoagulants or nonsteroidal anti-inflammatory drugs);
3. with myelodysplastic syndrome or abnormal baseline platelet counts of \< 80 × 10∧9/L or \> 450 × 10∧9/L;
4. hemoglobin \< 90g/L;
5. with a history of cerebral hemorrhage within 1 year;
6. in pregnancy.
Clinical data collection:
1. Patients basic characteristics.
2. Diagnosis and complicated diseases.
3. Medical treatment and interventional treatment.
Methods:
Blood samples are collected 5 days after the patients' taking clopidogrel to perform the genetic testing and determine the light transmittancy aggregation (LTA) and the serum levels of the parent clopidogrel, intermediate and active metabolites of clopidogrel. LTA is to re-determined 1 month after clopidogrel consumption. Clopidogrel low response is defined as the inhibition of platelet aggregation (IPA) in response to 5μM ADP is more than 40%. Clinical follow-up will be performed 1month, 6month, and 1year after the patients' included. Major adverse cardiovascular events (MACE) is set as death, non-fatal myocardial infarction (MI), ischemic stroke. Associations of the pharmacogenetic and pharmacokinetic factors with clopidogrel low response and clinical outcome will be analyzed.
Tests:
1. ADP-induced platelet aggregation: LTA in response to 5μM ADP.
2. Arachidonic acid (AA)-induced platelet aggregation: LTA in response to 1mM AA.
3. Simultaneous detection of clopidogrel, 2-oxo-clopidogrel and its thiol metabolite in human plasma by the high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method.
4. GWAS scan or genotyping of ABCB1,CYP2C19, paraoxonase 1 (PON1), CYP3A5, P2RY12.
Sample size: We plan to recruit 1800 patients.
Clinical follow-up: 1 month, 6 month, and 1 year after the patients' included.
Major adverse cardiovascular events (MACE): Death, non-fatal MI, ischemic stroke.
Minor adverse cardiovascular events: Hospitalization, revascularization, stent thrombosis (ARC definition) and minor, moderate, and major bleeding (TIMI definition).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
All recruited patients
Patients who receive stent implantation and aged \>18 years.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient aged \>18 years;
3. Signed inform consent.
Exclusion Criteria
2. taking medication that could interfere with the antiplatelet efficacy of clopidogrel (e.g. vitamin K antagonists, direct oral anticoagulants or nonsteroidal anti-inflammatory drugs);
3. with myelodysplastic syndrome or abnormal baseline platelet counts of \< 80 × 10∧9/L or \> 450 × 10∧9/L;
4. hemoglobin \< 90g/L;
5. with a history of cerebral hemorrhage within 1 year;
6. in pregnancy.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Natural Science Foundation of China
OTHER_GOV
The First Affiliated Hospital with Nanjing Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chunjian Li
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chunjian Li, Ph.D
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital with Nanjing Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Siller-Matula JM, Jilma B. Why have studies of tailored anti-platelet therapy failed so far? Thromb Haemost. 2013 Oct;110(4):628-31. doi: 10.1160/TH13-03-0250. Epub 2013 Jul 25.
Zong J, Tang Y, Wang T, Ullah I, Xu K, Wang J, Chen P, Chen Z, Zhu T, Chen J, Li J, Wang F, Yang L, Fan Y, Shi L, Gong X, Eikelboom JW, Zhao Y, Li C. Impact of Insulin Receptor Substrate-1 rs956115 and CYP2C19 rs4244285 Genotypes on Clinical Outcome of Patients Undergoing Percutaneous Coronary Intervention. J Am Heart Assoc. 2022 Aug 16;11(16):e025058. doi: 10.1161/JAHA.121.025058. Epub 2022 Aug 5.
Wang J, Wang J, Dong Z, Ma J, Teng J, Wang T, Zhang X, Gu Q, Ye Z, Ullah I, Tan C, Abdus S, Shi L, Gong X, Li C. An optimal window of platelet reactivity by LTA assay for patients undergoing percutaneous coronary intervention. Thromb J. 2021 Oct 19;19(1):73. doi: 10.1186/s12959-021-00323-5.
Xu K, Ye S, Zhang S, Yang M, Zhu T, Kong D, Chen J, Xu L, Li J, Zhu H, Wang F, Yang L, Zhang J, Fan Y, Ying L, Hu X, Zhang X, Chan NC, Li C. Impact of Platelet Endothelial Aggregation Receptor-1 Genotypes on Platelet Reactivity and Early Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention and Treated With Aspirin and Clopidogrel. Circ Cardiovasc Interv. 2019 May;12(5):e007019. doi: 10.1161/CIRCINTERVENTIONS.118.007019.
Ying L, Wang F, Zhang J, Yang L, Gong X, Fan Y, Xu K, Li J, Lu Y, Mei L, Zhou Z, Li C. Impact of hepatitis B virus (HBV) infection on platelet response to clopidogrel in patients undergoing coronary stent implantation. Thromb Res. 2018 Jul;167:119-124. doi: 10.1016/j.thromres.2018.04.017. Epub 2018 Apr 19.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NNSFC/81170181
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
002
Identifier Type: -
Identifier Source: org_study_id